Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$418.01 USD
+0.69 (0.17%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $418.23 +0.22 (0.05%) 6:26 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Balance Sheet
Fiscal Year End for Vertex Pharmaceuticals Incorporated falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 11,218 | 10,779 | 7,525 | 6,659 | 3,808 |
Receivables | 1,563 | 1,442 | 1,137 | 885 | 634 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 739 | 461 | 353 | 281 | 168 |
Other Current Assets | 624 | 554 | 546 | 308 | 214 |
Total Current Assets | 14,144 | 13,235 | 9,561 | 8,133 | 4,823 |
Net Property & Equipment | 1,159 | 1,108 | 1,094 | 959 | 745 |
Investments & Advances | 2,498 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 1,812 | 1,247 | 935 | 883 | 1,191 |
Intangibles | 1,928 | 1,692 | 1,402 | 1,402 | 1,402 |
Deposits & Other Assets | 895 | 522 | 111 | 49 | 158 |
Total Assets | 22,730 | 18,151 | 13,433 | 11,752 | 8,318 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 365 | 304 | 195 | 155 | 88 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2,655 | 2,127 | 1,679 | 1,405 | 1,117 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 527 | 312 | 268 | 317 | 130 |
Total Current Liabilities | 3,547 | 2,742 | 2,142 | 1,878 | 1,335 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 376 | 431 | 510 | 539 | 539 |
Other Non-Current Liabilities | 878 | 686 | 303 | 298 | 360 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 5,150 | 4,238 | 3,333 | 3,065 | 2,233 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 3 | 3 | 3 | 3 | 3 |
Capital Surplus | 7,450 | 7,387 | 6,881 | 7,894 | 7,938 |
Retained Earnings | 10,142 | 6,523 | 3,201 | 859 | -1,853 |
Other Equity | -14 | 1 | 16 | -68 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 17,580 | 13,913 | 10,100 | 8,687 | 6,085 |
Total Liabilities & Shareholder's Equity | 22,730 | 18,151 | 13,433 | 11,752 | 8,318 |
Total Common Equity | 17,580 | 13,913 | 10,100 | 8,687 | 6,085 |
Shares Outstanding | 257.60 | 256.60 | 254.20 | 260.00 | 257.10 |
Book Value Per Share | 68.25 | 54.22 | 39.73 | 33.41 | 23.67 |
Fiscal Year End for Vertex Pharmaceuticals Incorporated falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 11,218 | 11,928 | 11,236 | 10,414 | 10,779 |
Receivables | 1,563 | 1,539 | 1,556 | 1,548 | 1,442 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 739 | 689 | 604 | 535 | 461 |
Other Current Assets | 624 | 540 | 477 | 469 | 554 |
Total Current Assets | 14,144 | 14,696 | 13,873 | 12,966 | 13,235 |
Net Property & Equipment | 1,159 | 1,124 | 1,122 | 1,112 | 1,108 |
Investments & Advances | 2,498 | 1,700 | 1,357 | 1,082 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 1,812 | 1,729 | 1,538 | 1,360 | 1,247 |
Intangibles | 1,928 | 1,692 | 1,692 | 1,692 | 1,692 |
Deposits & Other Assets | 895 | 475 | 443 | 428 | 522 |
Total Assets | 22,730 | 21,726 | 20,349 | 18,974 | 18,151 |
Liabilities & Shareholders Equity | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 365 | 376 | 363 | 323 | 304 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2,655 | 2,907 | 2,598 | 2,326 | 2,127 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 527 | 316 | 391 | 377 | 312 |
Total Current Liabilities | 3,547 | 3,599 | 3,352 | 3,026 | 2,742 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 376 | 390 | 404 | 418 | 431 |
Other Non-Current Liabilities | 878 | 759 | 727 | 686 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 5,150 | 5,213 | 4,879 | 4,542 | 4,238 |
Shareholders Equity | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 3 | 3 | 3 | 3 | 3 |
Capital Surplus | 7,450 | 7,340 | 7,369 | 7,220 | 7,387 |
Retained Earnings | 10,142 | 9,174 | 8,138 | 7,223 | 6,523 |
Other Equity | -14 | -3 | -40 | -13 | 1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 17,580 | 16,513 | 15,470 | 14,432 | 13,913 |
Total Liabilities & Shareholder's Equity | 22,730 | 21,726 | 20,349 | 18,974 | 18,151 |
Total Common Equity | 17,580 | 16,513 | 15,470 | 14,432 | 13,913 |
Shares Outstanding | 257.60 | 258.10 | 257.50 | 257.00 | 256.60 |
Book Value Per Share | 68.25 | 63.98 | 60.08 | 56.16 | 54.22 |